Menu

U.S. FDA Drug and Product Approvals Explained: Publications and Documents

Summary

The FDA Drug and Product Approvals publications on Disabled World offer a range of articles and research relevant to medical advancements and safety. These publications include FDA announcements, research papers, and product releases covering topics such as new drug approvals like those for multiple sclerosis or Duchenne muscular dystrophy, medical device clearances such as glucose monitoring systems, and warnings regarding consumer products, like hand sanitizers or weight loss supplements. Many of the articles are peer-reviewed and offer updates, revisions, and insights that can be interesting, helpful, and of use to the general public, including seniors, people with disabilities, and those interested in staying informed about healthcare options and regulatory actions.

Searching the Database

The data table below lists items that may have been updated or revised, but the table defaults to sorting by descending publication date; you can search and sort by clicking column headers (JavaScript required). Items in this category are also distributed via our U.S. FDA Drug and Product Approvals Explained RSS feed.

U.S. FDA Drug and Product Approvals Explained: Publications and Resources (69 Items)
Title and DescriptionEdPublish
Revised

Cognoa ASD Diagnosis Aid is an aid for diagnosis of ASD in patients 18 months - 5 years of age who are at risk of developmental delay based on concerns of a parent, caregiver, or health care provider.


FDA authorizes Neurolutions IpsiHand, a brain-computer interface device that uses EEG technology to help stroke patients recover hand and arm function through rehabilitation.



U.S. FDA completes series of actions on review of OTC antiseptic active ingredients and issues final rule on safety and effectiveness of consumer hand sanitizers.


Teva Pharmaceuticals USA gains approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths for emergency treatment of allergic reactions in adults and pediatric patients who weigh more than 33 pounds.

U.S. FDA warns consumers about criminals forging FDA warning letters to target people who tried to purchase medicines online or over the phone.


FDA approves continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes.


FDA approval of MiniMed 670G hybrid closed looped diabetes device to automatically monitor glucose and provide appropriate basal insulin doses for individuals aged 7 to 13 with type 1 diabetes.


US FDA has permitted marketing of Dexcom G6 integrated continuous glucose monitoring (iCGM) system for determining blood glucose levels in children aged 2 and older and adults with diabetes.

Statement from FDA Commissioner Scott Gottlieb, M.D. on new steps to facilitate efficient generic drug review to enhance competition, promote access and lower drug prices.


U.S. Food and Drug Administration permitted the marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.


FDA approves Kymriah, the first U.S. gene therapy, offering new hope for children and young adults with hard-to-treat acute lymphoblastic leukemia.



U.S. Food and Drug Administration approves Radicava (edaravone) to treat amyotrophic lateral sclerosis, commonly referred to as Lou Gehrig's disease.

Ocrevus (ocrelizumab) has been approved to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).

Researchers create Blueprint for Transparency to advance the development of safe and effective new products.


Noctiva, desmopressin acetate, is a nasal spray for adults who awaken during the night to urinate (nocturnal polyuria).

Food and Drug Administration approves Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy.

Lawsuit claims U.S. FDA failed to adequately respond to concerns raised about health risks salon keratin hair products containing formaldehyde pose.

U.S. Food and Drug Administration approves Exondys 51 (eteplirsen) injection to treat patients with Duchenne muscular dystrophy (DMD).

Advocates such as E Cigarette Reviewed calling on US FDA to take evidence based approach to electronic cigarette technology.

Institute of Medicine (IOM) report recommendations for maintaining delicate balance of drug innovation and drug safety.


US FDA approves Intermezzo zolpidem tartrate sublingual tablets for insomnia characterized by night waking followed by difficulty returning to sleep.

FDA approval of tadalafil (Cialis) for benign prostatic hyperplasia symptoms and concurrent erectile dysfunction treatment in men with enlarged prostate.



U.S. Food and Drug Administration approves Boostrix vaccine to prevent tetanus diphtheria and pertussis (whooping cough) in people ages 65 and older.

FDA approved Lazanda (fentanyl) nasal spray for management of breakthrough pain in cancer patients 18 years and older already receiving and are tolerant to opioid therapy for underlying persistent cancer pain.

The FDA Pathway to Global Product Safety and Quality strategy to meet challenges posed by rapidly rising imports of FDA regulated products and complex global supply chain.

Sterile injectable gel to treat fecal incontinence in patients for whom other therapies such as diet change fiber therapy or anti-motility medications failed.

Toxoplasmosis is caused by the parasite Toxoplasma gondii and can cause serious health problems in people with compromised immune systems.


Sutent (sunitinib) approved for progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or have spread to other parts of the body.

Q fever is an infectious disease among serving soldiers and can cause acute or chronic illness after contact with infected animals or exposure to contaminated environments.


The U.S. Food and Drug Administration has approved Edurant (rilpivirine) in combination with other anti-retroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy.


The safety and effectiveness of Victrelis was evaluated in two phase 3 clinical trials with 1500 adult patients.

U.S. Food and Drug Administration has approved Tradjenta (linagliptin) tablets a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

FDA approved drug Horizant provides significant help in treating restless legs syndrome symptoms.

Calorie labeling on menus and menu boards in chain restaurants retail food establishments and vending machines.

U.S. Food and Drug Administration (FDA) approves Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer.


FDA approves Zostavax a live attenuated virus vaccine for the prevention of shingles in individuals 50 to 59 years of age.

Data from clinical studies showed Edarbi tablets (azilsartan medoxomil) to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs.


Congress passed the Orphan Drug Act because it recognized that adequate drugs for many rare diseases have not been developed.

FDA approves Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults.

Natroba provides another option for the topical treatment of head lice infestations.

The FDA has received multiple reports of adverse events associated with the use of Fruta Planta and Reduce Weight Fruta Planta.

EMD Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis.


Cymbalta a non-narcotic pain reliever has shown to significantly reduce chronic low back pain and chronic pain due to osteoarthritis.

Tuberous Sclerosis Alliance Announces FDA Approval of First Drug to Treat Tuberous Sclerosis Complex.


PRADAX is an alternative for Canadians at high risk of stroke due to atrial fibrillation.

Beyaz is the first and only OC approved to raise folate levels in women who choose an OC for birth control.

FDA has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).

FDA has approved Krystexxa for adults with gout unresponsive to conventional therapy, offering new hope but requiring careful monitoring for allergic reactions.



The U.S. Food and Drug Administration has approved the pediatric use of Protopam Chloride.

Actavis receives approval from FDA to market Atomoxetine HCl capsules for treatment of attention deficit hyperactivity disorder (ADHD).

Ella is a drug that can cause abortions but is misleadingly labeled as an effective Emergency Contraceptive.


A rise in undisclosed side-effects of prescription medications like Vioxx and Avandia have put the U.S. FDA under fire with consumer watch groups calling for agency reform.


US FDA has approved vaccines for the 2010-2011 influenza season in the United States including H1N1.

XSense laboratory test that may be suitable for population-based screening for Fragile X Syndrome.

FDA has approved Implantable Miniature Telescope (IMT) to improve vision in patients with age-related macular degeneration (AMD).

Circadin is Approved in the EU for Treatment of Primary Insomnia in Patients Aged 55 or Over for up to 3 Months.

Jevtana (cabazitaxel) chemotherapy drug used in combination with steroid prednisone to treat prostate cancer.

FDA clearance to market new lactate test on the epoc Blood Analysis System.

FTY720 (fingolimod) represents significant advance as efficacious MS oral treatment for people with relapsing remitting multiple sclerosis.

Dental amalgam is a mixture of metals composed of liquid mercury powdered amalgam alloy composed primarily of silver tin, and copper.

Injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.

Clearance from the FDA for use of the LensAR Laser System for anterior capsulotomy during cataract surgery.

Redsense Medical Receives FDA Clearance for the Redsense Safety Device for Home/Self use During Home Hemodialysis.

IOM report recommends framework to evaluate science behind health claims for foods and drugs equal rigor in assessing food claims and drug approvals.


Introducing the first and only oral contraceptive to bring estradiol valerate together with dienogest in a new dosing regimen.

FDA approves VIMOVO for arthritis patients at risk of NSAID-associated gastric ulcers, combining naproxen pain relief with stomach protection.



Approval of Asclera (polidocanol) Injection a sclerotherapy treatment for uncomplicated spider and reticular veins.


Requirement that device manufacturers provide readily available information in certain premarket applications on pediatric patients.

Lotion formulation of the well-tolerated retinoid adapalene for the treatment of acne.

Key: the first check mark indicates the publication carries an editor's note; the second indicates a footnote.

Note: Disabled World compiles disability-related publications as a resource. Inclusion does not imply endorsement by Disabled-World.com. To submit disability-related articles and peer-reviewed manuscripts and papers, ensure submissions comply with our guidelines. For questions, please contact us.

Back to U.S. FDA Drug and Product Approvals Explained Index.

Permalink:

Database of <a href="https://www.disabled-world.com/medical/pharmaceutical/fda-2/">U.S. FDA Drug and Product Approvals Explained documents, papers, and peer reviewed publications</a> - Disabled World (DW).

While we strive to provide accurate, up-to-date information, our content is for general informational purposes only. Please consult qualified professionals for advice specific to your situation.